CONSOLIDATION THERAPY WITH ENTECAVIR CAN PREVENT POST-TREATMENT HBsAg REBOUND IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALPHA

被引：0
|
作者：
Brouwer, W. P. [1 ]
Sonneveld, M. J. [1 ]
Xie, Q. [2 ]
Zhang, N. [3 ]
Zeuzem, S. [4 ]
Tabak, F. [5 ]
Zhang, Q. [6 ]
Simon, K. [7 ]
Akarca, U. S. [8 ]
Streinu-Cercel, A. [9 ]
Hansen, B. [1 ]
Janssen, H. L. [10 ]
机构：
[1] Erasmus MC, Gastroenterol & Hepatol, Rotterdam, Netherlands
[2] Jiao Tong Univ, Ruijin Hosp, Gastroenterol & Hepatol, Infect Dis, Shanghai 200030, Peoples R China
[3] Fudan Univ, Zhong Shan Hosp, Gastroenterol & Hepatol, Shanghai 200433, Peoples R China
[4] Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, Gastroenterol & Hepatol, Frankfurt, Germany
[5] Cerrahpasa Med Fac, Gastroenterol & Hepatol, Istanbul, Turkey
[6] Fudan Univ, Shanghai Publ Hlth Ctr, Gastroenterol & Hepatol, Shanghai 200433, Peoples R China
[7] Wroclaw Med Univ, Gastroenterol & Hepatol, Wroclaw, Poland
[8] Ege Univ, Tip Fak, Gastroenterol & Hepatol, Bornova, Turkey
[9] Natl Inst Infect Dis, Gastroenterol & Hepatol, Bucharest, Romania
[10] Toronto Western & Gen Hosp, Univ Hlth Network, Ctr Liver Dis, Gastroenterol & Hepatol, Toronto, ON, Canada
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30873-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0669
引用
收藏
页码：S572 / S573
页数：2
相关论文
共 50 条
  • [31] THE PERFORMANCE OF HBSAG BASED STOPPING-RULES FOR HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON DEPENDS UPON HBV GENOTYPE
    Sonneveld, Milan J.
    Rijckborst, Vincent
    Arends, Pauline
    Boucher, Charles A.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2011, 54 : 1023A - 1024A
  • [32] HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
    Yang, Song
    Xing, Huichun
    Wang, Yuming
    Hou, Jinlin
    Luo, Duande
    Xie, Qing
    Ning, Qin
    Ren, Hong
    Ding, Huiguo
    Sheng, Jifang
    Wei, Lai
    Chen, Shijun
    Fan, Xiaoling
    Huang, Wenxiang
    Pan, Chen
    Gao, Zhiliang
    Zhang, Jiming
    Zhou, Boping
    Chen, Guofeng
    Wan, Mobin
    Tang, Hong
    Wang, Guiqiang
    Yang, Yuxiu
    Xu, Dongping
    Dong, Peiling
    Wang, Qixin
    Wang, Jue
    Bognar, Fernando A.
    Xu, Daozhen
    Cheng, Jun
    VIROLOGY JOURNAL, 2016, 13 : 1 - 9
  • [33] HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
    Song Yang
    Huichun Xing
    Yuming Wang
    Jinlin Hou
    Duande Luo
    Qing Xie
    Qin Ning
    Hong Ren
    Huiguo Ding
    Jifang Sheng
    Lai Wei
    Shijun Chen
    Xiaoling Fan
    Wenxiang Huang
    Chen Pan
    Zhiliang Gao
    Jiming Zhang
    Boping Zhou
    Guofeng Chen
    Mobin Wan
    Hong Tang
    Guiqiang Wang
    Yuxiu Yang
    Dongping Xu
    Peiling Dong
    Qixin Wang
    Jue Wang
    Fernando A. Bognar
    Daozhen Xu
    Jun Cheng
    Virology Journal, 13
  • [34] PRESENCE OF ONLY WILDTYPE VIRUS IS THE STRONGEST DETERMINANT OF HBVDNA UNDETECTABILITY AND HBSAG CLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON
    Sonneveld, M. J.
    Rijckborst, V.
    Zeuzem, S.
    Heathcote, E. J.
    Simon, K.
    Senturk, H.
    Pas, S. D.
    Hansen, B. E.
    Janssen, H. L.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S24 - S24
  • [35] Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Buster, Erik H. C. J.
    Hansen, Bettina E.
    Buti, Maria
    Delwaide, Jean
    Niederau, Claus
    Michielsen, Peter P.
    Flisiak, Robert
    Zondervan, Pieter E.
    Schalm, Solko W.
    Janssen, Harry L. A.
    HEPATOLOGY, 2007, 46 (02) : 388 - 394
  • [36] HBeAg and HBV DNA kinetics in HBsAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)
    Fried, M. W.
    Liaw, Y. F.
    Luo, K. X.
    Lau, G. K. K.
    Piratvisuth, T.
    Cooksley, G.
    Marcellin, P.
    Flisiak, R.
    Popescu, M.
    Button, P.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S183 - S183
  • [37] Use of on-Treatment HBsAg Level and HBeAg Index Can Early Predict Sustained Virological Response in Chronic Hepatitis B, HBeAg Positive Patients Treated With Peginterferon ALPHA-2A
    Phisalprapa, Pochamana
    Charatchamenwitthaya, Phunchai
    Chainuvati, Siwaporn P.
    Nimanong, Supot
    Pausawasdi, Nonthalee
    Prachayakul, Varaytt
    Pongprasubchai, Supot
    Leelakusolvong, Somchai
    Manatsathit, Satapom
    Kachintorn, Udom
    Tanwandee, Tawesak
    GASTROENTEROLOGY, 2011, 140 (05) : S931 - S931
  • [38] PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB) WITH A MAINTAINED VIROLOGICAL RESPONSE TO ENTECAVIR ACHIEVED HBSAG CLEARANCE WHEN SWITCHED TO PEGINTERFERON ALFA-2A THERAPY (THE OSST STUDY)
    Ning, Qin
    Han, Meifang
    Sun, Yongtao
    Jiang, Jia-ji
    Tan, Deming
    Hou, Jinlin
    Tang, Hong
    Sheng, Ji-Fang
    Jiang, Michael
    HEPATOLOGY, 2011, 54 : 1010A - 1011A
  • [39] The combination therapy of Peginterferona and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk
    Xiong, Fang
    Bao, Xuli
    Gu, Na
    Guo, Jia
    Wang, Jinhuan
    Ma, Yanpin
    Yu, Lele
    Gao, Yao
    Tan, Bingqin
    Lu, Jun
    INFECTION GENETICS AND EVOLUTION, 2020, 78
  • [40] Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B
    van Campenhout, Margo J. H.
    van Boemmel, Florian
    Pfefferkorn, Maria
    Fischer, Janett
    Deichsel, Danilo
    Boonstra, Andre
    van Vuuren, Anneke J.
    Berg, Thomas
    Hansen, Bettina E.
    Janssen, Harry L. A.
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (06) : 610 - 619
12345